A controlled clinical trial of daily and intermittent regimens of rifampicin plus ethambutol in the retreatment of patients with pulmonary tuberculosis in Hong Kong. A Hong Kong Tuberculosis Treatment Services/Brompton Hospital/British Medical Research Council investigation.
D000293:Adolescent; D000328:Adult; D000906:Antibodies / Q000032:analysis; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D003875:Drug Eruptions / Q000209:etiology; D004359:Drug Therapy, Combination; D004417:Dyspnea / Q000139:chemically induced; D004977:Ethambutol / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007565:Jaundice / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D011859:Radiography; D012293:Rifampin / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D013183:Sputum / Q000382:microbiology; D014397:Tuberculosis, Pulmonary / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000382:microbiology
D000906:Antibodies; D004977:Ethambutol; D012293:Rifampin